EA028420B1 - Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа - Google Patents

Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа Download PDF

Info

Publication number
EA028420B1
EA028420B1 EA201590332A EA201590332A EA028420B1 EA 028420 B1 EA028420 B1 EA 028420B1 EA 201590332 A EA201590332 A EA 201590332A EA 201590332 A EA201590332 A EA 201590332A EA 028420 B1 EA028420 B1 EA 028420B1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
compound
cetuximab
combination
mutation
Prior art date
Application number
EA201590332A
Other languages
English (en)
Russian (ru)
Other versions
EA201590332A1 (ru
Inventor
Джордано Капонигро
Даррин Стьюарт
Лор Муту-Де Парсеваль
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA028420(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201590332A1 publication Critical patent/EA201590332A1/ru
Publication of EA028420B1 publication Critical patent/EA028420B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201590332A 2012-08-07 2013-08-05 Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа EA028420B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (2)

Publication Number Publication Date
EA201590332A1 EA201590332A1 (ru) 2015-06-30
EA028420B1 true EA028420B1 (ru) 2017-11-30

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590332A EA028420B1 (ru) 2012-08-07 2013-08-05 Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа

Country Status (39)

Country Link
US (1) US9474754B2 (2)
EP (2) EP2882440B1 (2)
JP (3) JP6342396B2 (2)
KR (1) KR102112885B1 (2)
CN (1) CN104519887B (2)
AR (1) AR092045A1 (2)
AU (1) AU2013299841B8 (2)
CA (1) CA2879548C (2)
CL (1) CL2015000294A1 (2)
CO (1) CO7200273A2 (2)
CY (1) CY1122143T1 (2)
DK (1) DK2882440T3 (2)
EA (1) EA028420B1 (2)
EC (1) ECSP15008695A (2)
ES (1) ES2717911T3 (2)
GT (1) GT201500025A (2)
HK (1) HK1211831A1 (2)
HR (1) HRP20190537T1 (2)
HU (1) HUE042877T2 (2)
IL (1) IL236934B (2)
IN (1) IN2015DN00450A (2)
JO (1) JOP20130236B1 (2)
LT (1) LT2882440T (2)
MA (1) MA37829A1 (2)
MX (1) MX359403B (2)
MY (1) MY176031A (2)
NZ (1) NZ703940A (2)
PE (2) PE20150673A1 (2)
PH (1) PH12015500246B1 (2)
PL (1) PL2882440T3 (2)
PT (1) PT2882440T (2)
RS (1) RS58734B1 (2)
SG (1) SG11201500321YA (2)
SI (1) SI2882440T1 (2)
TN (1) TN2015000027A1 (2)
TR (1) TR201904980T4 (2)
TW (1) TWI607754B (2)
UA (1) UA115786C2 (2)
WO (1) WO2014025688A1 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6342396B2 (ja) * 2012-08-07 2018-06-13 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
MA38522A1 (fr) 2013-03-21 2017-10-31 Novartis Ag Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3392348A3 (en) * 2014-06-16 2018-11-21 Worldwide Innovative Network Method for selecting personalized tri-therapy for cancer treatment
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
US20180256557A1 (en) * 2015-08-28 2018-09-13 Giordano Caponigro Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer
EP3355886A1 (en) * 2015-08-28 2018-08-08 Novartis AG Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
FI3463345T3 (fi) * 2016-06-03 2023-01-31 Farmaseuttisia yhdistelmiä
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
KR20200036880A (ko) * 2017-08-03 2020-04-07 노파르티스 아게 3세대 EGFR 타이로신 키나아제 억제제 및 Raf 억제제의 치료적 조합물
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
EP4593831A1 (en) * 2022-09-26 2025-08-06 Mapkure, LLC Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib
WO2025262686A1 (en) * 2024-06-20 2025-12-26 Ilan Paz Devices, systems and methods for optimized, personalized administration of oral dosage forms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2011028540A1 (en) * 2009-08-24 2011-03-10 Genentech, Inc. Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
WO2011046894A1 (en) * 2009-10-12 2011-04-21 Glaxosmithkline Llc Combination
WO2013070996A1 (en) * 2011-11-11 2013-05-16 Novartis Ag Method of treating a proliferative disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
MY150697A (en) 2007-04-10 2014-02-28 Exelixis Inc Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
MX360157B (es) * 2010-11-08 2018-10-24 Novartis Ag Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.
US20140275174A1 (en) 2011-11-10 2014-09-18 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
JP6342396B2 (ja) * 2012-08-07 2018-06-13 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds
WO2011028540A1 (en) * 2009-08-24 2011-03-10 Genentech, Inc. Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2011046894A1 (en) * 2009-10-12 2011-04-21 Glaxosmithkline Llc Combination
WO2013070996A1 (en) * 2011-11-11 2013-05-16 Novartis Ag Method of treating a proliferative disease

Also Published As

Publication number Publication date
CA2879548C (en) 2020-07-21
EP3574904A1 (en) 2019-12-04
JP2020019780A (ja) 2020-02-06
WO2014025688A1 (en) 2014-02-13
AU2013299841B8 (en) 2017-01-05
EP3574904B1 (en) 2026-03-04
CY1122143T1 (el) 2020-11-25
RS58734B1 (sr) 2019-06-28
AU2013299841A1 (en) 2015-02-12
HUE042877T2 (hu) 2019-07-29
PE20150673A1 (es) 2015-05-20
LT2882440T (lt) 2019-04-25
AU2013299841A8 (en) 2017-01-05
PH12015500246A1 (en) 2015-03-30
ES2717911T3 (es) 2019-06-26
JP6342396B2 (ja) 2018-06-13
IL236934B (en) 2018-11-29
CA2879548A1 (en) 2014-02-13
EP2882440B1 (en) 2019-02-27
ECSP15008695A (es) 2019-03-29
JOP20130236B1 (ar) 2021-08-17
KR102112885B1 (ko) 2020-05-19
MY176031A (en) 2020-07-22
PE20191655A1 (es) 2019-11-07
UA115786C2 (uk) 2017-12-26
IN2015DN00450A (2) 2015-06-26
US20150265616A1 (en) 2015-09-24
EA201590332A1 (ru) 2015-06-30
PH12015500246B1 (en) 2015-03-30
JP2018109022A (ja) 2018-07-12
TR201904980T4 (tr) 2019-05-21
AU2013299841B2 (en) 2016-11-24
KR20150040905A (ko) 2015-04-15
GT201500025A (es) 2017-09-28
MA37829A1 (fr) 2017-01-31
CO7200273A2 (es) 2015-02-27
JP6974669B2 (ja) 2021-12-01
TWI607754B (zh) 2017-12-11
BR112015002384A8 (pt) 2019-07-30
SI2882440T1 (sl) 2019-05-31
CN104519887A (zh) 2015-04-15
CN104519887B (zh) 2017-06-27
AR092045A1 (es) 2015-03-18
JP2015524472A (ja) 2015-08-24
SG11201500321YA (en) 2015-04-29
PT2882440T (pt) 2019-04-23
MX359403B (es) 2018-09-26
CL2015000294A1 (es) 2015-05-08
EP2882440A1 (en) 2015-06-17
TW201410247A (zh) 2014-03-16
HRP20190537T1 (hr) 2019-06-28
US9474754B2 (en) 2016-10-25
JP6595024B2 (ja) 2019-10-23
BR112015002384A2 (pt) 2017-07-04
TN2015000027A1 (en) 2016-06-29
HK1211831A1 (zh) 2016-06-03
PL2882440T3 (pl) 2019-07-31
MX2015001732A (es) 2015-06-03
NZ703940A (en) 2018-04-27
DK2882440T3 (da) 2019-05-06
HK1204976A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
EA028420B1 (ru) Фармацевтические комбинации, содержащие ингибитор b-raf, ингибитор egfr и, необязательно, ингибитор pi3k-альфа
JP6742391B2 (ja) 併用療法
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK40051622A (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor
BR112015002384B1 (pt) Combinações farmacêuticas compreendendo um inibidor de b-raf e um inibidor de egfr, e seus usos
EA040191B1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ TJ TM